Biosafety of non-surface modified carbon nanocapsules as a potential alternative to carbon nanotubes for drug delivery purposes

Alan C.L. Tang, Gan Lin Hwang, Shih Jung Tsai, Min Yao Chang, Zack C.W. Tang, Meng Da Tsai, Chwan Yao Luo, Allan S. Hoffman, Patrick C.H. Hsieh

研究成果: Article同行評審

20 引文 斯高帕斯(Scopus)

摘要

Background: Carbon nanotubes (CNTs) have found wide success in circuitry, photovoltaics, and other applications. In contrast, several hurdles exist in using CNTs towards applications in drug delivery. Raw, non-modified CNTs are widely known for their toxicity. As such, many have attempted to reduce CNT toxicity for intravenous drug delivery purposes by post-process surface modification. Alternatively, a novel sphere-like carbon nanocapsule (CNC) developed by the arc-discharge method holds similar electric and thermal conductivities, as well as high strength. This study investigated the systemic toxicity and biocompatibility of different non-surface modified carbon nanomaterials in mice, including multi-walled carbon nanotubes (MWCNTs), single-walled carbon nanotubes (SWCNTs), carbon nanocapsules (CNCs), and C 60 fullerene (C 60). The retention of the nanomaterials and systemic effects after intravenous injections were studied. Methodology and Principal Findings: MWCNTs, SWCNTs, CNCs, and C 60 were injected intravenously into FVB mice and then sacrificed for tissue section examination. Inflammatory cytokine levels were evaluated with ELISA. Mice receiving injection of MWCNTs or SWCNTs at 50 μg/g b.w. died while C 60 injected group survived at a 50% rate. Surprisingly, mortality rate of mice injected with CNCs was only at 10%. Tissue sections revealed that most carbon nanomaterials retained in the lung. Furthermore, serum and lung-tissue cytokine levels did not reveal any inflammatory response compared to those in mice receiving normal saline injection. Conclusion: Carbon nanocapsules are more biocompatible than other carbon nanomaterials and are more suitable for intravenous drug delivery. These results indicate potential biomedical use of non-surface modified carbon allotrope. Additionally, functionalization of the carbon nanocapsules could further enhance dispersion and biocompatibility for intravenous injection.

原文English
文章編號e32893
期刊PloS one
7
發行號3
DOIs
出版狀態Published - 2012 三月 22

All Science Journal Classification (ASJC) codes

  • 多學科

指紋

深入研究「Biosafety of non-surface modified carbon nanocapsules as a potential alternative to carbon nanotubes for drug delivery purposes」主題。共同形成了獨特的指紋。

引用此